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Background/aim: To investigate the correlation between depressive-anxiety symptoms, mixed features, disease activity, and functional
status in patients with rheumatoid arthritis (RA) in the light of the shared underlying etiology in both disorders.
Materials and methods: The study included 556 patients with RA. RA disease activity was measured using the Disease Activity Score
28-joint count C reactive protein (DAS28-CRP), and the patients were evaluated by a Health Assessment Questionnaire (HAQ). The
Hospital Anxiety and Depression Scale (HADS), Mood Disorder Questionnaire (MDQ), and Modified Hypomania Checklist (mHCL)
were used to evaluate the mixed depression and bipolarity status of the patients.
Results: Of the patients, 430 (77.3%) were female and 126 (22.7%) were male. The median age was 57 years, the median HAQ score
was 0.55 points, and the median DAS28-CRP score was 4.1 points. The evaluation of the patients by DAS28-CRP revealed that 58.5%
of the patients had moderate and severe disease activity, while only 23.4% of them were in remission. The group using the combination
of synthetic disease-modifying anti-rheumatic drugs (sDMARD) and steroid therapy had significantly higher HAD-depression, HADanxiety, mHCL, DAS28-CRP, HAQ, and MDQ scores than the group using sDMARD alone. The grouping of the patients based on the
DAS28-CRP cut-off scores showed that the patients with moderate and severe disease activity had significantly higher HADS, mHCL,
MDQ scores than those in remission and those with mild disease activity (p < 0.001).
Conclusion: Disease severity and functional status in RA can be affected by comorbid anxiety-depressive and mixed symptoms.
Therefore, clinicians should consider screening the depressive-anxiety and mixed mood symptoms of RA patients. Moreover, patients
who use steroid therapy are more susceptible to mood symptoms (anxiety, depression, bipolarity), which should also be considered
during the follow-up of patients.
Key words: Arthritis, rheumatoid, bipolar disorder/psychology, depression/psychology, prevalence

1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease characterized by inflammation in the
synovium of the joints and destruction of the cartilage and
bone in the affected joints [1]. The primary presentation
of the disease is joint involvement and is essential for the
diagnosis of the disease. Nevertheless, there are many other
associated systemic symptoms and comorbidities affecting
the functional status and quality of life of RA patients [2].
RA patients commonly have comorbid psychiatric illnesses
such as anxiety and depressive disorders. However, the
etiology underlying this comorbidity has not been fully
understood [3].

Chronic inflammation has a major role in the
pathophysiology of depression, especially for mood
disorders [4]. Many studies investigating the pathogenesis
of RA symptoms have reported chronic inflammation
and increased cytokine levels in RA patients compared to
healthy controls [5]. Autoantibodies found in the serum
of patients with RA have provided many clues for the
pathophysiology [6]. RA patients usually have infiltration
of joint tissue (synovium) by immune cells such as B
cells, T cells, and macrophages that release a range of
proinflammatory cytokines and promote inflammation,
resulting in tissue destruction. Although epidemiological
studies have identified environmental and genetic factors
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contributing to the risk of developing RA, the exact cause
of autoimmune response in these patients has not yet
been fully elucidated [7]. On the other hand, studies have
shown a correlation between autoimmune and psychiatric
diseases, especially bipolar disorder, major depressive
disorder, and schizophrenia [8].
Long-term treatment plays a crucial role in chronic
diseases and positive clinical outcomes of patients
suffering from these conditions including mood disorders
and RA depend on their adherence to treatment. Although
the prognosis of RA and treatment adherence are affected
by comorbid psychiatric illnesses [9], elimination of
psychiatric conditions has been shown to increase the
treatment success for RA [10]. There are numerous studies
in the literature investigating depressive symptoms in
RA. However, to the best of our knowledge, there is no
study on mixed depression in RA. Depression with mixed
features has been included in the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) [11].
Recent studies have shown a more severe course of mixed
depression and poorer treatment response compared
to pure depression [12]. Therefore, this study aimed to
investigate the correlation between depressive-anxiety
symptoms, mixed features, disease activity, and functional
status in patients with RA in the light of the shared
underlying etiology in both disorders.
2. Materials and methods
2.1. Study design
This cross-sectional study included 556 patients, who
presented to the rheumatology department between 1
September and 31 December 2020 and who were diagnosed
with RA according to the 2010 College of Rheumatology
/ European League Against Rheumatism (ACR/EULAR)
classification criteria [13].
2.2. Participants
The study inclusion criteria were set as follows: patients
aged 18 years and over who were regularly followed up
and treated for RA in the rheumatology clinic, who did
not have a history of alcohol and substance abuse, and who
were not on psychiatric medication.
The exclusion criteria were set as follows: patients
aged under 18 years, who were on psychiatric therapy,
had a history of alcohol and substance abuse, other
uncontrolled medical disorders, mental retardation and
overlap syndromes with RA. Patients were included in the
study consecutively according to inclusion and exclusion
criteria.
2.3. Data collection
All patients’ demographic characteristics and clinical
data were analyzed. The clinical data included duration of
disease, drugs used at the time of admission and before,

habits (smoking, alcohol, etc.), and history of other
systemic diseases. Laboratory analysis was performed to
determine C-reactive protein (CRP), albumin (g/dL) levels,
and erythrocyte sedimentation rate (ESR). Complete blood
count analysis was performed to leukocyte, neutrophil,
lymphocyte, and thrombocyte count.
All patients underwent systemic and rheumatologic
physical examinations. RA disease activity was measured
using the Disease Activity Score 28-joint count-CRP
(DAS28-CRP). Moreover, the patients were evaluated by
a Health Assessment Questionnaire (HAQ). DAS28-CRP
and HAQ scores were calculated by a rheumatologist. The
mixed depression and bipolarity states of the patients were
evaluated using individual and anonymous questionnaires.
All measurement tools used in the study have been
evaluated by the Turkish validity and reliability studies.
2.4. Measurement tools
2.4.1. Hospital anxiety and depression scale (HADS)
HADS is a self-report questionnaire developed by Zigmond
and Snaith in 1983 to measure levels of anxiety and
depression [14]. It consists of 14 items. Seven of the items
(odd numbers) measure anxiety, while the other seven
items (even numbers) measure depression. It is a useful
scale to screen depression and anxiety states of patients with
chronic diseases who are treated in outpatient and clinical
settings. Its design offers ease of use for nonpsychiatric
departments. However, a complete clinical evaluation is
required to make the definitive diagnosis of anxiety and
depression. Each item of this scale is rated on a 4-point
Likert scale (0–3), with scores ranging between 0 and 21
points for each of the two subscales. A score between 0
and 7 indicates a normal state, while a score of 8 and above
indicates anxiety and depression symptoms. Aydemir et al.
conducted the Turkish validity and reliability study on the
questionnaire [15].
2.4.2. Modified Hypomania Checklist (mHCL)
mHCL is a self-rating screening tool for evaluating manic
symptoms in current depressive episode [16]. mHCL
consists of 32 questions to screen manic and hypomanic
symptoms. There is no cut-off score for m-HCL-32. At least
three manic symptoms are required for mixed depression
diagnosis according to the DSM-5 [11]. Altinbaş et al.
conducted the Turkish validity and reliability study on the
checklist [16].
2.4.3. Mood Disorder Questionnaire (MDQ)
MDQ is a self-assessment instrument developed by
Hirschfeld et al. in 2003 [17]. It consists of 17 questions to
screen bipolar disorder. In the questionnaire, 13 questions
about possible symptoms are answered either “yes” or “no”,
and 4 questions assess the level of functioning, cooccurring
symptoms, previous diagnosis of BD, and family history
of bipolar disorder (BP). The criteria of at least 7 or more
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symptoms, two or more cooccurring symptoms, and the
presence of moderate or severe impairment should be met
in order to evaluate screening positive (MDQ standard
cut-off). The cut-off value for the questionnaire has been
reported as 7, with a sensitivity of 0.64 and a specificity
of 0.77. Konuk et al. conducted the Turkish validity and
reliability study on the questionnaire [18].
2.4.4. Disease Activity Score 28-joint count C reactive
protein (DAS28-CRP)
DAS28-CRP is used to determine the severity of RA using
CRP along with the number of sensitive and swollen
joints. The number of swollen joints is determined by a
visual analog scale and CRP levels. The DAS28-CRP score
ranges between 0 and 9.4, with <2.6 indicating remission,
≥2.6 and ≤3.2 low disease activity, >3.2 and ≤5.1 moderate
disease activity, and >5.1 indicating severe disease activity.
2.4.5. Health Assessment Questionnaire (HAQ)
HAQ is a comprehensive instrument designed to evaluate
a patient’s health status. HAQ is one of the measures of
the ACR Core Data Set for the assessment of RA disease
activity and patient-oriented outcomes, including
disability, drug-associated side effects, discomfort, cost of
care, and mortality. It includes 20 items divided into the
eight subcategories of dressing, arising, eating, walking,
hygiene, reaching, gripping, and usual activities to
determine patients’ ability to use upper or lower limbs.
Each item of HAQ is rated on a 4-point scale ranging
from 0 to 3, where 0 = without any difficulty, 1=with some
difficulty, 2=with much difficulty, and 3=unable to do.
The final HAQ index ranges from 0 to 3 and is scored by
averaging the items from all eight categories. A HAQ score
<0.3 is considered normal; however, the average HAQ of
the population has been shown to increase with increasing
age [19]. A higher HAQ score indicates higher disability. In
RA patients, the minimum clinically significant difference
in serial measurement of HAQ scores has been shown to
be 0.22 at the group level [19].
2.5. Statistical analysis
SPSS V22.0 statistical software package (SPSS, Inc.,
Chicago, IL, USA) was used for all data analyses.
Categorical variables were presented as numbers
(percentage). Numerical variables were presented as
mean ± standard deviation (SD) or median (min – max)
according to their distribution. The Kolmogorov–Smirnov
test was used to check the normality assumption of
numeric variables. The independent-samples t-test was
used for intergroup comparisons of normally distributed
numeric variables, while the Mann–Whitney’s U test
was used for nonnormally distributed variables. The chisquare test was used to evaluate categorical data. Three
groups’ comparisons were done with Kruskall–Wallis test.
Posthoc analyses were performed by Mann–Whitney U
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test with Bonferroni correction, and the p value p < 0.05 / 3
= 0.017 was considered as significant. The odds ratio (OR)
with a 95% confidence interval (CI) was used to report the
strength of association. Spearman’s correlation analysis
(r) was used for correlation analysis. Factors affecting
anxiety, depression, mixed depression, and bipolarity
were analyzed using the backward linear regression
analysis. Variables found to be statistically significant
in univariate analyses were included in linear regression
analysis. Correlations between risk factors and outcomes
are presented as odds ratios (ORs) and 95% CI. The level
of statistical significance was set at p < 0.05.
3. Results
3.1. Sociodemographic and clinical characteristics of
patients
Distribution of sex in our samples revealed that 430
(77.3%) were women. The median age of the patients was
57 years, and the median age at diagnosis was 57 years. The
median disease duration was 4 years. The assessment of
the patients’ disease activity and functional status revealed
a median HAQ score of 0.55 and a median DAS28-CRP
score of 4.1 points. Of the patients, 386 (69.4%) had
positive RF and 371 (66.7%) had positive anti-CCP. The
treatment regimens of the patients were also evaluated.
Three hundred and eleven of the patients were on steroids,
with a median steroid dose of 2.5 and a median duration
of steroid use of 2 years. Of the patients, 207 (37.2%) were
using synthetic disease-modifying anti-rheumatic drugs
(sDMARD), while 37 (6.7%) were using sDMARD with
biologic DMARD (bDMARD). One patient (0.2%) was
receiving only bDMARD. The clinical and laboratory
characteristics of the patients are summarized in Table 1.
A total of 24 patients were excluded from the study due to
psychiatric treatment.
3.2. Comparison of Mood Disorder Questionnaire Scores
by treatment regimens and disease activity
Of the patients, 253 (45.5%) had depression, 216 (38.8%)
had anxiety, and 194 (34.9%) had mixed depression
according to the cut-off scores of psychiatric screening
scales. The comparison of the patients’ psychiatric scale
scores by treatments are shown in Table 2.
The comparison of the HAD-depression (HAD-D),
HAD-anxiety (HAD-A), mHCL, DAS28-CRP, HAQ, and
mood disorders scale scores of the patients who were on
sDMARD or on sDMARD in combination with steroid
therapy revealed that the patients receiving sDMARD plus
steroid therapy had significantly higher scores in all scales.
The sample was divided into three groups based on
their DAS28-CRP scores. The patients with moderate and
severe disease activity had significantly higher HADS,
mHCL, MDQ scores than both those in remission and
those with mild disease activity (p < 0.001). However, there
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Table 1. The patients’ features and laboratory values.
Female, n (%)

430 (77.3%)

Age, years

57 (20–81)

Disease Onset Age

52 (17–80)

Disease duration (years)

4 (0.5–25)

Rheumatoid factor, n (%)

386 (69.4%)

Anti–citrullinated protein antibody, n (%)

371 (66.7%)

WBC

7.2 (1.0–21.5)

Neutrophil (10³ / ϻL)

4.2 (1.1–55.6)

Lymphocyte (10³ / ϻL)

2.0 (0.7–9.7)

CRP

6.3 (0.03–112.1)

ESR

16 (2–67)

Albumin (g / L)

4.3 (2.5–5.1)

HAQ score

0.55 (0.05–2.2)

DAS28-CRP

4.1 (1.2–6.4)

Disease activity according to
DAS28-CRP

Treatment regimens

Remission

130 (23.4%)

Mild

101 (18.2%)

Moderate - Severe

325 (58.5%)

sDMARD

207 (37.2%)

sDMARD + Steroid

285 (51.3%)

bDMARD + sDMARD

37 (6.7%)

bDMARD + sDMARD + Steroid

14 (2.5%)

bDMARD

1 (0.2%)

Streoid

12 (2.2%)

Categorical variables expressed as n (%)
Continuous variables expressed as median (min-max) values
bDMARD Biologic Disease Modyfiying Anti-Rheumatic Drugs, CRP C-Reactive protein (mg/dL,
normal range 0–5), DAS28-CRP Disease Activity Score28-C-Reactive protein, ESR Erythrocyte
Sedimentation Rate (mm/h; normal range 0–20), HAQ Health Assessment Questionnaire, NLR
Neutrophil / Lymphocyte ratio, SD Standard deviation, sDMARD Synthehic Disease Modyfiying
Anti-Rheumatic Drugs, WBC white blood cell (103/mm3).
Table 2. Comparison of patients’ psychiatric scale scores according to treatments.
sDMARD
(n = 207)

sDMARD + Steroid
(n = 285)

z value

p value

2 (0–13)

4 (0–13)

–5.7

<0.001*

a

HAD-D

5 (0–19)

8 (0–19)

–6.1

<0.001*

HAD-Aa

4 (0–17)

7 (0–18)

–5.4

<0.001*

mHCL

8 (0–22)

10 (0–23)

–5.4

<0.001*

MDQa

a

sDMARD Synthehic Disease Modyfiying Anti-Rheumatic Drugs, HAD-A Hospital
Anxiety and Depression Scale-Anxiety, HAD-D Hospital Anxiety and Depression
Scale-Depression; mHCL Modified Hypomania Checklist, MDQ Mood Disorder
Questionnaire.
Continuous variables expressed as median (min-max) values.
a
p value has been calculated using Mann Whitney U test.
*Significant at p < 0.05 level.
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was no significant difference between the remission group
and the mild disease activity group in terms of psychiatric
scale scores. (Table 3).
3.3. Correlation and regression analysis of
rheumatological and psychiatric scale scores
The evaluation of the correlations between mood disorders
and RA disease activity revealed a moderate correlation
between MDQ and HAQ scores (r = 0.41, p < 0.001)
and between MDQ and DAS28-CRP scores (r = 0.59, p
< 0.001). Moreover, there was a moderate correlation
between HAD-D and HAQ scores (r = 0.39, p < 0.001)
and between HAD-D and DAS28-CRPscores (r = 0.60, p
< 0.001). Furthermore, the evaluation of the correlations
of HAD-A showed a moderate correlation with the HAQ
score (r = 0.36, p < 0.001) and a moderate correlation with
DAS28-CRP (r = 0.50, p < 0.001). The evaluation of the
correlations of mHCL revealed a moderate correlation

with HAQ score (r = 0.41, p < 0.001) and a moderate
correlation with DAS28-CRP (r = 0.59, p < 0.001).
The linear regression analysis of the patient groups by
HAQ and DAS28-CRP scores showed that DAS28-CRP
scores increased with the increase in mHCL, HAD-D,
and MDQ scores and that an increase in HAQ scores was
associated with the increase in mHCL scores (Table 4).
4. Discussion
The present study demonstrated that the group using
sDMARD plus steroid therapy had significantly higher all
mood disorder scale scores such as HADS-D, HADS-A,
mHCL, MDQ, and disease activity and functional status
scale scores such as DAS28-CRP and HAQ compared to
the group receiving sDMARD monotherapy. The grouping
of the patients based on the DAS28-CRP cut-off scores
showed that the patients with moderate and severe disease

Table 3. Comparison of patients’ mood disorder scale scores of the patients according to the disease activity.
Remission

Mild

Moderate and severe

p value

2.1 ± 2.8 / 1.6–2.6

1.72 ± 2.0 /1.3–2.1

5.4 ± 3.7 / 5.0–5.8

<0.001*

a

HAD-D

4.7 ± 3.5 / 4.1–5.3

4.5 ± 3.1 / 4.0–5.1

9.5 ± 4.6 / 9.0–10.0

<0.001*

a

HAD-A

5.3 ± 3.7 / 4.7–6.0

4.5 ± 2.7 / 4.0–5.0

8.2 ± 4.2 / 7.8–8.7

<0.001*

mHCLa

7.2 ± 3.0 / 6.8–7.8

7.1 ± 2.6 / 6.6–7.6

11.3 ± 4.2 / 10.8–11.8

<0.001*

MDQa

HAD-A Hospital Anxiety and Depression Scale-Anxiety, HAD-D Hospital Anxiety and Depression ScaleDepression, mHCL Modified Hypomania Checklist, MDQ Mood Disorder Questionnaire, SD Standard
deviation.
Unless otherwise states, values are presented as Mean ± SD / 95% CI.
a
p value has been calculated using Mann Whitney U test with Bonferroni correction, significant at p < 0.017
level.
Table 4. Linear Regression Analysis of Mood Scales by HAQ and DAS28-CRP.
Scale
mHCL
HAD-A
HAD-D
MDQ

Beta

t

%95 CI

p value

HAQ

0.189

2.55

0.004 – 0.031

0.011*

DAS28-CRP

0.249

3.91

0.036 – 0.110

<0.001*

HAQ

0.042

0.62

–0.008 – 0.016

0.530

DAS28-CRP

0.009

0.16

–0.031 – 0.036

0.875

HAQ

0.086

1.17

–0.005 – 0.019

0.242

DAS28-CRP

0.271

4.3

0.038 – 0.102

<0.001*

HAQ

0.155

1.72

–0.009 – 0.041

0.085

DAS28-CRP

0.151

2.0

–0.018 – 0.121

0.045*

DAS28-CRP Disease Activity Score28-C-Reactive protein, HAD-A Hospital Anxiety and
Depression Scale-Anxiety, HAD-D Hospital Anxiety and Depression Scale-Depression,
HAQ Health Assessment Questionnaire, mHCL Modified Hypomania Checklist, MDQ
Mood Disorder Questionnaire.
*Significant at p < 0.05 level.
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activity had significantly higher HADS, mHCL, MDQ
scores than those in remission and those with mild disease
activity. The higher depression and bipolarity scores of the
patients receiving steroid therapy indicate an association
between steroid therapy and psychiatric symptoms.
The prevalence of psychiatric symptoms is high
in inflammatory chronic conditions such as RA. A
metaanalysis of 72 studies, including a total of 13189
patients, reported a depression prevalence between
9.5% [20] and 41.5% [21] in patients with RA. In their
systematic review and metaanalysis of a small number of
studies using gold-standard clinical interviews, Matcham
et al. found that 16.8% of RA patients, mostly consisting
of female and older adult patients, had major depression
[22]. A Taiwan study by Hsu et al. comparing 2570 RA
patients with 2570 controls without RA found a higher
incidence of bipolar disorder (OR = 2.13, 95% CI=1.12–
4.24, p=0.013) in RA patients compared to controls [23].
Another study comparing 11782 RA patients with 57973
age- and sex-matched controls found a higher prevalence
of bipolar disorder in RA patients compared to controls
[24]. A metaanalysis by Charoenngam N. et al. reported
an approximately two-fold higher frequency of bipolar
disorder development in patients with RA compared to the
healthy population [25]. We found that nearly half of our
sample reported higher depression scores, while one-third
has probable anxiety disorders according to the HADS cutoff scores. Besides, nearly one-third of the patients with
RA reported higher scores on MDQ cut-off score. These
relatively high scores of mood disorder scales might be due
to the self-rating nature of the scales. Such varying results
between studies may be due to the diagnostic criteria of
depression used by different studies as well as the high
number of psychometric instruments to screen depression
[26]. Nevertheless, the bidirectional relationship between
mood disorders and inflammatory autoimmune diseases
such as RA should be further studied in long-term followup studies.
Inflammation is the underlying mechanism proposed
for both RA and mood disorders [8,9]. RA is a welldefined, immune-mediated chronic inflammatory disease
characterized by increased levels of proinflammatory
cytokines, including interleukin 6 (IL6), interleukin
1ß (IL1ß), and tumor necrosis factor 1α (TNFα) [27].
Although the pathogenesis of depression has not been
fully elucidated, the effect of immune-mediated pathways
on the pathogenesis has been the subject of many studies
[28]. Metaanalyses have shown higher concentrations of
cytokines such as IL1ß, TNFα, and IL6 in the peripheral
blood of patients with depression compared to healthy
controls [28–30]. Symptoms associated with depressive
disorders such as asthenia and depressed mood pose a
major health burden for many countries, particularly for

those with chronic diseases such as spondyloarthritis and
RA [31]. Patients suffering from joint diseases usually
manifest these symptoms, affecting their productivity
and quality of life [32]. Depression is the most common
psychiatric disorder accompanying RA due to a probable
increase in the prevalence of fatigue, pain, poor healthrelated quality of life, physical disabilities, and increased
cost of care [30]. In addition to the impact of RA causing
depressive symptoms, chronic inflammation has been
shown to have a major contribution to the pathophysiology
of mood disorders such as bipolar and depressive disorder
[4,33]. Although the exact mechanism of this condition
is unknown, there are various hypotheses. One of these
hypotheses is chronic neuroinflammation involved in the
pathogenesis of bipolar disorder [34]. Numerous studies
have shown increased levels of peripheral inflammatory
markers such as TNFα, IL4, IL6, and IL10 in bipolar
patients [35]. Poor quality of life and functional impairment
have been reported as risk factors for the development
of anxiety disorder and major depressive disorder in RA
patients [36]. Our study showed that patients with RA,
who were receiving steroid therapy and had moderate
and severe disease activity, had higher psychiatric scale
scores, which is consistent with the previously suggested
hypotheses about the higher prevalence of bipolar disorder
in RA. However, the multivariate analysis revealed an
insignificant correlation between bipolar disorder and RA
[24]. Moreover, the levels of inflammatory cytokine were
not evaluated in our study, which can be considered as a
limitation.
The importance of identifying and measuring
depression in patients with RA is not only to treat a
worsening comorbid disease but also to prevent the
functional decline and decrease in response to treatment
caused by depression in patients with RA [37]. Depression
may mitigate with remission of rheumatoid arthritis [38].
Furthermore, depression treatments have previously been
shown to support this immuno-psychiatric association,
for example, it has been shown that antidepressants lower
inflammation, while a high level of inflammation at baseline
predicts a lower treatment efficacy for most treatments
[39]. In our study, depression scales were found to be
lower in patients with remission and lower disease activity.
Depression has been shown to increase the limitation
of movement [40] and reduce treatment response and
remission [41] in RA patients. Furthermore, it has also
been reported that depression reduces the continuity of
anti-rheumatic drugs [41]. Previous studies have attributed
this to different reasons [42]. Other comorbid conditions
such as cardiovascular diseases associated with RA are also
often associated with depression [43]. Depression has been
shown to increase suicidal [44] and nonsuicidal mortality
[45] in RA patients. Our results revealed that depression
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was strongly correlated with the disease activity and
severity in RA. However, the cross-sectional design of
our study does not allow us to conclude that this result
is the cause or consequence. There is a need for further
cohort follow-up studies with a larger sample size to find
an answer to this question. On the other hand, we did not
find a correlation between the HAQ score and the MDQ
score. The fact that MDQ is not a highly selective scale in
terms of sensitivity and specificity and is used to screen the
general population may be the reason for the absence of
a significant correlation. However, 32 hypomanic-manic
symptoms are screened on the mHCL scale. Increased
hypomanic-manic symptoms and higher screening scores
are significantly correlated with the HAQ score. Manic
symptoms in bipolar disorder may indicate a more severe
disease course. Therefore, the fact that depression was
not found to be significant might be associated with the
abovementioned reasons.
The correlation between steroid exposure and
neuropsychiatric disorders has been investigated in many
studies and it has been shown that high-dose steroid
exposure such as Cushing’s syndrome is associated with
behavioral disorders ranging from severe depression
to mania [19]. Steroids are frequently used to suppress
inflammation in patients with RA, the psychiatric
and cognitive effects of which are well defined [46].
Depression, mania, and hypomania, mania, the primary
symptoms of bipolar disorder, have also been reported to
arise with steroid use [47]. A prospective study reported
depression and hypomania symptoms in 10% and 26%
of the patients, respectively, who received steroid therapy
for 8 days [48]. Although not clearly demonstrated, the
potential mechanism of action is the toxic effect of steroids
on hippocampal neurons and other brain regions [49],
the presynaptic effects on dopaminergic and cholinergic
neurons [50], and the inhibition of serotonin release [51].
In line with this evidence, we found that the depression,
anxiety, and hypomanic symptom scores were higher in
the DMARD plus steroid group and severe disease activity.
This result might be the consequence of steroid therapy.
Many confounding factors such as psychosocial stressors
and inflammatory changes as a shared etiologic factor for
both disorders could not be excluded.
Our study has several limitations. First, the crosssectional nature of the study is the major limitation.
Second, RA patients were recruited from a single center,
which limits the generalizability of the results despite the
relatively big sample size of the study. Third, there was
no structured psychiatric interview for the patients, and
only screening tools were used to identify psychiatric
symptoms. Fourth, the heterogeneity of the sample is
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another limitation, considering that most of the patients
had advanced disease.
In conclusion, both mood disorders and RA are
diseases in which inflammatory processes continue
their existence as common etiological pathways. Disease
severity and functional status in RA can be affected by
comorbid anxiety-depressive and mixed symptoms, as
demonstrated by this study. Therefore, clinicians should
consider screening the depressive-anxiety and mixed mood
symptoms of RA patients. Moreover, patients who use
steroid therapy are more susceptible to mood symptoms
(anxiety, depression, bipolarity), which should also be
considered during the follow-up of patients. There is a
need for long-term controlled studies with a larger sample
size to evaluate the impact of psychiatric comorbidities
and the casual relationship with steroid use in RA.
To sum up,
-Depressive, anxiety and mixed mood symptoms are
common in RA patients.
-Psychiatric symptoms are associated with disease
activity and functionality.
-Patients on steroid treatment are more vulnerable to
represent all type of mood symptoms.
-Clinicians should consider the impact of mood
symptoms during the diagnosis and treatment process of
RA.
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